Legend Biotech to present CARVYKTI and pipeline data at ASH 2026

Legend Biotech Corporation announced on November 4, 2026 that multiple abstracts were accepted for the 2026 American Society of Hematology Annual Meeting, taking place December 12 to 15 in New Orleans, Louisiana¹. The program includes two oral presentations, four posters, and an additional ePublication.¹

On CARVYKTI (ciltacabtagene autoleucel, cilta-cel), the CITADEL observational study evaluated a preemptive steroid strategy to prevent immune effector cell parkinsonism, finding a 1.6% rate following CARVYKTI at four U.S. academic centers compared to a historical rate of 2.9%¹. A CARTITUDE-4 subgroup analysis showed durable outcomes in lenalidomide- and daratumumab-refractory relapsed or refractory multiple myeloma patients treated with CARVYKTI as early as second line, with nearly 60% progression-free at 30 months and median overall survival not reached¹.

On pipeline programs, updated data from the first-in-human study of LB2501 showed overall and complete response rates of 100% among eight patients treated at dose level 2, with response durations of up to five months as of the data cutoff¹. LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, described as the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance¹, and is being evaluated in an ongoing Phase 1 open-label study in China under identifier NCT07002112¹. Follow-up data will also be presented from the Phase 1 study of LUCAR-G39D, a dual-targeting CD19/CD20 allogeneic CAR-T candidate¹ in relapsed or refractory B-cell non-Hodgkin lymphoma.

Legend Biotech develops and markets CARVYKTI with collaborator Johnson & Johnson.¹ The oral presentations are scheduled for December 12, 2026, with poster sessions on December 12 and 13.